Trinity Biotech plc has secured regulatory approval from an in-country healthcare product regulatory authority for the commencement of upstream manufacturing activities of its Uni-Gold™ HIV rapid test under a new offshored and outsourced production model. This approval is the final major regulatory milestone required to fully implement the company's new manufacturing approach, following prior authorization from the World Health Organization (WHO) in November 2025. The transition to the new model is expected by the company to expand gross margins, improve working capital efficiency, and enhance scalability to support future demand for Uni-Gold™ HIV. No other beneficiary organizations were mentioned in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652224-en) on February 10, 2026, and is solely responsible for the information contained therein.